Exciting news was revealed on June 18, 2014 with the announcement the Mocetinostat Orphan Drug Designation from the FDA. Information gleaned from a Phase 1/2 study of Mocetinostat showed that when used alongside Azacitidine (Vidaza) this combination provided efficacious treatment for patients with myelodysplastic syndromes. Patients who were at intermediate or high risk myelodysplastic syndromes,[…]
Mocetinostat Orphan Drug Designation Received
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Orphan Drug Status Tags: acute myeloid leukemia Jul 14, 2014
Belinostat Early Approval for Lymphoma is Welcomed By Many
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approval News, FDA Approved 2014 Jul 03, 2014
The accelerated approval of Belinostat by the FDA on July 3, 2014 is exciting news for the medical and pharmaceutical communities. Known as the brand name Beleodaq, which is marketed by Topotarget, Belinostat is expected to be available for patients by the end of July 2014. As a formidable treatment for unresectable or relapsed peripheral[…]
Ibrutinib Proves Formidable Treatment for CLL or SLL Patients
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: chronic lymphocytic leukemiaIbrutinib Jun 30, 2014
Patients suffering from chronic lymphocytic leukemia {CLL} or small lymphocytic lymphoma {SLL} can breathe easier with the latest findings regarding Ibrutinib. Study results revealed at the beginning of June 2014 showed that the powerful anti-cancer drug Ibrutinib elicited a significant improvement for patients with either chronic lymphocytic leukemia or small lymphocytic lymphoma in both overall[…]
Pancreatic Cancer Predicted to Become the Second Cause of U.S. Cancer Deaths
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: EGFRPaclitaxel Jun 19, 2014
Startling news emerged on May 19, 2014 with an ominous report issued from the Pancreatic Cancer Action Network. The report has predicted that pancreatic cancer will become the #2 cause of cancer deaths in the year 2030, bumping colorectal cancer to the third slot. This sobering information comes in response to recent changes in American[…]
Idelalisib Is a Leader in Oncology Treatment
Chemotherapeutic / Anti-Neoplastic, NDA Tags: chronic lymphocytic leukemiaCLLIdelalisibRituximab Jun 18, 2014
Idelalisib has captured the attention of pharmaceutical research and development teams with the latest data touting its targeted treatment for both unresectable non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The FDA accepted Gilead Sciences’ new drug application early in 2014 for the treatment of refractory indolent NHL, and the target review date for the[…]
FDA Grants Accelerated Approval to Ceritinib For ALK- Positive NSCLC
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014 Tags: Crizotinib Jun 09, 2014
Phase 1 clinical trial results for Ceritinib have revealed affirmative results, leading the FDA to grant an accelerated approval for this impressive drug. Deemed to be “highly active” in the fight against ALK-rearranged non-small-cell lung cancer, Ceritinib is also twenty times more potent than Crizotinib. The exciting results from Novartis’s Phase 1 trial were recently[…]
Vemurafenib and Cobimetinib – A Dynamic Duo in the Fight Against Melanoma
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: kinase inhibitor May 29, 2014
Encouraging news for patients with Melanoma was disseminated on May 7, 2014 with the announcement that Vemurafenib and Cobimetinib look like the next powerful drug duo in the fight against this deadly cancer. Roche and Exelixis revealed that early stage trials of these formidable drugs have shown significant rates of extended survival, with plans underway[…]
Ofatumumab FDA Approved to Treat Chronic Lymphocytic Leukemia
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014, Monoclonal Antibodies / mAb Tags: chronic lymphocytic leukemia May 06, 2014
The recent approval of Ofatumumab by the FDA is exciting news for the medical and pharmaceutical world. As a monoclonal antibody used to treat chronic lymphocytic leukemia, Ofatumumab garnished a Supplemental Biologic License Application in late April 2014. Known as the brand name drug Arzerra, which is marketed by both GlaxoSmithKline and Genmab this unique[…]
Regorafenib Proves to Show Additional Benefits
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Patent Expiration 2020 Tags: EUregorafenib Apr 28, 2014
Regorafenib is a formidable treatment for colon cancer, and in late 2013 it has received another new approval for GIST in Japan and Europe. Known as the trade name Stivarga, Regorafenib was approved in both Japan and Europe for the treatment of gastrointestinal stromal tumors. The FDA approved Regorafenib two years ago and added the[…]
EU Approves Cabozantinib for Metastatic Medullary Thyroid Carcinoma
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, EU Approved 2014 Tags: EGFREU Apr 17, 2014
The end of March 2014 brought exciting news from the EU with the announcement of their approval of Cabozantinib for unresectable medullary thyroid carcinoma. Known as the brand name Cometriq and marketed by Exelixis, Cabozantinib works by inhibiting the activity of MET, RET and VEGFR tyrosine kinases. Cases of medullary thyroid carcinoma are virulent and[…]
